Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.

ABSTRACT:

Background

Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community.

Methods

In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression.

Results

Higher mi

SUBMITTER: Peters BA 

PROVIDER: S-EPMC6785875 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature